ALZpath and Quanterix Join Forces to Enhance Alzheimer's Research with Expanded Licensing Agreement

ALZpath and Quanterix Expand Their Strategic Licensing Agreement

In a significant step towards enhancing Alzheimer's disease research, ALZpath, Inc., a prominent player in blood test-based diagnostic solutions, and Quanterix Corporation have announced an expansion of their licensing agreement. This collaboration aims to advance the use of ALZpath's proprietary pTau217 antibody technology across Quanterix's innovative Simoa® research platform.

The foundation of this partnership was laid with an initial agreement in 2023, wherein Quanterix opted for ALZpath's pTau217 antibody to develop the Simoa® ALZpath pTau217 Assay. This assay has been pivotal in expanding the understanding of neurodegenerative diseases, having featured in 161 peer-reviewed studies since its launch. One of the most notable mentions includes a landmark study published in Nature in December 2025, showcasing the potential of scaling pTau217 blood tests to better grasp the global prevalence of Alzheimer's disease.

The recent expansion of the licensing agreement broadens the scope of ALZpath’s pTau217 antibody into new investigative avenues within Alzheimer's biomarker research. Advances in biomarker biology and analytical capabilities enable researchers to scrutinize disease-associated pathology with unprecedented specificity. The collaboration aims to fuse ALZpath's advanced antibody technologies with Quanterix's established Simoa® platform, which is well-regarded for its extensive installed research systems.

Mike Banville, CEO of ALZpath, expressed enthusiasm about the partnership's progress, stating, "The Simoa ALZpath pTau217 assay has become a fundamental resource across global Alzheimer's research. This expanded agreement presents an excellent opportunity to merge advances in biomarker research with more sensitive analytical technologies, providing new avenues for scientific exploration and understanding Alzheimer’s disease more deeply."

Both companies share a mission to democratize access to blood-based testing for Alzheimer's disease, bringing high-performance antibody tools to both research and clinical applications. This collaboration underscores ALZpath's commitment to partnering with industry leaders, enhancing the possibilities for accurately diagnosing and monitoring Alzheimer's disease on a broader scale.

As the healthcare landscape evolves, the integration of advanced technology and innovative research methodologies will likely play a crucial role in tackling Alzheimer's disease. With the evolution of blood-based biomarkers, researchers have the potential to pivot towards more meaningful insights, ultimately aiding in better treatment and monitoring of this complex condition.

Through strategic partnerships like that of ALZpath and Quanterix, the future of Alzheimer's diagnostic technology appears to be promising, with advancements that might help us unlock the mysteries of this debilitating illness. If you wish to learn more about ALZpath's innovative approaches and their collaboration with Quanterix, you can visit their official site at ALZpath and follow them on social media platforms.